-
CDE publicly solicits opinions on two research technical guidelines
Time of Update: 2021-10-20
From October 12th to 13th, the CDE official website issued a notice on the public solicitation of two research technical guidelines, namely the "Guiding Principles for Toxicology Research on Ancient Classical Chinese Medicine Compound Preparations" and "Technical Guidelines for Clinical Research on Rabies Vaccines for Human Use" Principles (Draft for Comment) .
-
Issued by the National Health Commission: Maternal and Child Safety Action Improvement Plan (2021-2025)
Time of Update: 2021-10-20
On the basis of continuous improvement of treatment capabilities, all levels of critically ill maternal and neonatal treatment centers must pay close attention to the implementation of scribing and zoning responsibilities, strengthen guidance to lower-level medical institutions, and establish a high-level linkage and efficient consultation and referral mechanism to further smooth The green channel for critically ill referrals will ensure the safety of pregnant women and newborns .
-
Drug Administration: A batch of Nanning Baolai medical equipment is being recalled
Time of Update: 2021-10-20
actively recalled the ultrasonic scalerNanning Baolai Medical Devices Co.
actively recalled the ultrasonic scalerNanning Baolai Medical Equipment Co.
produced its ultrasonic scaler (model/specification: P5L, batch number: P5L21022601, product numbers: 03210320, 03210321, 03210322, 03210323, 03210324, 03210325, 03210326, 03210327, 03210328, 03210329) for active recall .
-
Deqi Pharmaceuticals will publish the research results of ATG-101 and ATG-017 at the 2021 SITC annual meeting
Time of Update: 2021-10-20
The poster details are as follows:Abstract Number: 227Title: Computational semi-mechanical pharmacology model of PD-L1/4-1BB bispecific antibody ATG-101 for the treatment of solid tumors and non-Hodgkin's lymphoma (NHL)Publication time: November 12-14, 2021, 7:00-17:00 (US Eastern Time)Speaker: Dr.
-
Buchang Pharmaceuticals and its wholly-owned subsidiary intend to acquire 100% equity of Beijing Chengrui
Time of Update: 2021-10-20
On October 15, Buchang Pharmaceutical issued an announcement stating that in order to meet Buchang Pharmaceutical’s future business development needs, promote the smooth implementation of the company’s overall strategy, enhance the company’s overall operating environment and external image, and realize the company’s planning, the company and its wholly-owned subsidiaries Shenzhou Pharmaceutical plans to acquire 100% equity of Beijing Chengrui .
-
700 million cardiovascular injections market welcomes "spoilers" again
Time of Update: 2021-10-20
The reason why Qilu Pharmaceutical can occupy the main market is that the industry analysis believes that the main reason is that esmolol hydrochloride injection has the characteristics of fast onset and short action time, and it has a wide range of clinical use and large dosage.
-
12 blockbuster sprints for the first class of new Chinese medicines are listed!
Time of Update: 2021-10-20
On October 9th, Kangyuan Pharmaceutical submitted a clinical application for the new drug of Jiuwei Shufeng Pingchuan Granules, which is the 37th class 1 new drug declared for Chinese patent medicine this year .
-
Yifeng has another 12 pharmacies, a detail reveals that Hubei may have big moves
Time of Update: 2021-10-20
On the evening of October 12, Dahu shares, whose main business is agriculture, issued an announcement that its wholly-owned subsidiary Dehai Medical Trade and its wholly-owned grandson company Dehai
-
Xinhua Pharmaceutical Clindamycin Phosphate Injection Passed the Consistency Evaluation of Generic Drugs
Time of Update: 2021-10-20
On October 13, Xinhua Pharmaceutical issued an announcement stating that the company received the Clindamycin Phosphate Injection (2ml: 0.
6g) to the National Medical Products Administration CDE for the registration application materials for the quality and efficacy consistency evaluation of generic drugs and was accepted.
-
Pioneer of Innovative Tumor Immune AI Drugs-Xunbaihui Biotechnology completed Series B financing, Coatue led the investment
Time of Update: 2021-10-20
Xunbaihui is an innovative drug company with unique technologies in the discovery of new targets for tumor immunotherapy and the development of antibody drugs .
Xunbaihui uses high-throughput functional genomics and artificial intelligence technology to find new targets for tumor immune drugs and develop effective antibody drugs .
-
Tonghua Dongbao's super fast-acting insulin lispro injection was approved for parallel phase III and phase I clinical trials
Time of Update: 2021-10-20
On October 13th, Tonghua Dongbao issued an announcement stating that the company submitted on March 28, 2021, the company submitted a type II communication regarding the parallel implementation of phase III clinical trials and phase I clinical trials of super fast-acting insulin lispro injection (THDB0206) in China.
-
ADC drug innovation has entered a golden development period, and domestic and foreign pharmaceutical companies are competing for layout
Time of Update: 2021-10-20
In recent years, with the continuous maturity of ADC drug research and development technology, global ADC drug innovation has gradually entered a golden development period from the early "bumpy development", and a large number of domestic and foreign pharmaceutical companies have also begun to vie for deployment .
-
How to enhance the competitiveness of the Chinese medicine industry "going to the sea"
Time of Update: 2021-10-20
In the opinion of analysts, although there are many reasons for restricting the export of Chinese medicine to the sea, the main problem affecting the development of Chinese medicine overseas market is that Chinese medicine has so far lacked a unified scientific standard that can be recognized by Western countries .
-
The State Food and Drug Administration issued a drug inspection notice that 7 batches of drugs produced by 5 companies were unqualified
Time of Update: 2021-10-20
According to the inspection by Hunan Provincial Institute of Drug Inspection, the 3 batches of orlistat capsules produced by Zhongshan Wanhan Pharmaceutical Co.
is not in compliance with the regulations after inspection by Jiangsu Food and Drug Administration and Research Institute, and the non-compliant items are content determination .
-
Industry observation: Benefiting from the expansion of pharmaceutical companies, a number of pharmaceutical machinery companies increased their business in the biomedical sector in the first three quarters
Time of Update: 2021-10-20
On April 2 this year, Tuoxin Pharmaceutical announced that it intends to raise 395 million yuan to expand production, research and development and supplement working capital.
Regarding performance growth, the company mentioned that “benefiting from the rapid expansion of domestic vaccine and pharmaceutical manufacturers, the company’s biomedical sector business has grown rapidly .
-
During the month, the controlling shareholders of a number of pharmaceutical companies dissolved their pledges
Time of Update: 2021-10-20
41%; net profit attributable to shareholders of listed companies was 964 million yuan, a year-on-year increase of 34.
41%; net profit attributable to shareholders of listed companies was 964 million yuan, a year-on-year increase of 34.
-
TOP10 antidepressants reshuffle!
Time of Update: 2021-10-20
In addition, Futhiaxetine Hydrobromide Tablets are the most sought-after; Escitalopram oxalate oral solution, No company has been approved for products such as desvenlafaxine succinate sustained-release tablets and fluoxetine hydrochloride oral solution, involving Chengdu Kanghong Pharmaceutical | Chengdu Dikang Pharmaceutical, Zhejiang Jianfeng Pharmaceutical, Yichang Renfu Pharmaceutical, etc.
-
In-depth interpretation: What is the resistance of Merck's new crown oral drug and the risk of drug mutation?
Time of Update: 2021-10-20
Denison believes that due to the mechanism of action of the new coronavirus, it is unlikely that Molnupiravir will develop resistance .
-
With the same target, over ten domestic layouts of Hengrui are making the fastest progress. Who will become the leader?
Time of Update: 2021-10-20
In March of this year, the phase II INTR@PID BTC 047 of M7824 used alone for the second-line treatment of locally advanced or metastatic biliary tract cancer (BTC) failed to reach the primary endpoint again, and the clinical trial was terminated again .
-
Guangdong Provincial Food and Drug Administration released the results of random inspections of drugs for 4 varieties and 4 batches that did not meet the requirements
Time of Update: 2021-10-20
On October 12, the Guangdong Provincial Food and Drug Administration issued the 8th phase of the 2021 drug random inspection information: 1797 batches of 861 varieties were tested to meet the drug standard requirements, and 4 batches of 4 varieties including loofah and Pudilan anti-inflammatory tablets were tested.
